Annual EBITDA
-$45.01 M
-$5.35 M-13.48%
December 31, 2023
Summary
- As of February 7, 2025, CRDF annual EBITDA is -$45.01 million, with the most recent change of -$5.35 million (-13.48%) on December 31, 2023.
- During the last 3 years, CRDF annual EBITDA has fallen by -$26.18 million (-138.94%).
- CRDF annual EBITDA is now -1972.18% below its all-time high of -$2.17 million, reached on December 31, 2011.
Performance
CRDF EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$12.50 M
-$60.00 K-0.48%
September 30, 2024
Summary
- As of February 7, 2025, CRDF quarterly EBITDA is -$12.50 million, with the most recent change of -$60.00 thousand (-0.48%) on September 30, 2024.
- Over the past year, CRDF quarterly EBITDA has dropped by -$1.79 million (-16.68%).
- CRDF quarterly EBITDA is now -638.68% below its all-time high of $2.32 million, reached on December 31, 2018.
Performance
CRDF Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$46.00 M
-$1.79 M-4.04%
September 30, 2024
Summary
- As of February 7, 2025, CRDF TTM EBITDA is -$46.00 million, with the most recent change of -$1.79 million (-4.04%) on September 30, 2024.
- Over the past year, CRDF TTM EBITDA has dropped by -$1.91 million (-4.33%).
- CRDF TTM EBITDA is now -6312.04% below its all-time high of -$717.40 thousand, reached on March 31, 2011.
Performance
CRDF TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CRDF EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -13.5% | -16.7% | -4.3% |
| 3 y3 years | -138.9% | -13.2% | -34.8% |
| 5 y5 years | -189.0% | -13.2% | -34.8% |
CRDF EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -58.5% | at low | -40.3% | at low | -62.0% | at low |
| 5 y | 5-year | -182.8% | at low | -220.2% | at low | -188.9% | at low |
| alltime | all time | -1972.2% | at low | -638.7% | at low | -6312.0% | at low |
Cardiff Oncology EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$12.50 M(+0.5%) | -$46.00 M(+4.0%) |
| Jun 2024 | - | -$12.44 M(+14.9%) | -$44.21 M(+0.8%) |
| Mar 2024 | - | -$10.83 M(+5.9%) | -$43.88 M(-2.5%) |
| Dec 2023 | -$45.01 M(+13.5%) | -$10.23 M(-4.5%) | -$45.01 M(+2.1%) |
| Sep 2023 | - | -$10.71 M(-11.5%) | -$44.09 M(+4.3%) |
| Jun 2023 | - | -$12.11 M(+1.2%) | -$42.29 M(+4.2%) |
| Mar 2023 | - | -$11.96 M(+28.5%) | -$40.59 M(+2.3%) |
| Dec 2022 | -$39.67 M(+39.6%) | -$9.31 M(+4.4%) | -$39.67 M(-0.3%) |
| Sep 2022 | - | -$8.91 M(-14.3%) | -$39.77 M(+5.4%) |
| Jun 2022 | - | -$10.40 M(-5.8%) | -$37.75 M(+10.6%) |
| Mar 2022 | - | -$11.04 M(+17.3%) | -$34.12 M(+20.1%) |
| Dec 2021 | -$28.40 M(+50.8%) | -$9.41 M(+36.7%) | -$28.40 M(+11.0%) |
| Sep 2021 | - | -$6.89 M(+1.6%) | -$25.59 M(+11.5%) |
| Jun 2021 | - | -$6.78 M(+27.4%) | -$22.95 M(+13.9%) |
| Mar 2021 | - | -$5.32 M(-19.3%) | -$20.16 M(+7.0%) |
| Dec 2020 | -$18.84 M(+18.3%) | -$6.60 M(+55.3%) | -$18.84 M(+16.7%) |
| Sep 2020 | - | -$4.25 M(+6.5%) | -$16.14 M(+1.0%) |
| Jun 2020 | - | -$3.99 M(-0.4%) | -$15.98 M(-0.7%) |
| Mar 2020 | - | -$4.00 M(+2.6%) | -$16.09 M(+1.1%) |
| Dec 2019 | -$15.92 M(+2.2%) | -$3.90 M(-4.4%) | -$15.92 M(+64.2%) |
| Sep 2019 | - | -$4.08 M(-0.3%) | -$9.70 M(-10.5%) |
| Jun 2019 | - | -$4.10 M(+6.9%) | -$10.83 M(+5.7%) |
| Mar 2019 | - | -$3.83 M(-265.3%) | -$10.25 M(-6.2%) |
| Dec 2018 | -$15.58 M(-31.2%) | $2.32 M(-144.5%) | -$10.92 M(-29.5%) |
| Sep 2018 | - | -$5.22 M(+48.4%) | -$15.50 M(+8.9%) |
| Jun 2018 | - | -$3.52 M(-22.1%) | -$14.22 M(-12.7%) |
| Mar 2018 | - | -$4.51 M(+100.0%) | -$16.29 M(-18.0%) |
| Dec 2017 | -$22.63 M | -$2.26 M(-42.8%) | -$19.85 M(-18.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | -$3.94 M(-29.3%) | -$24.39 M(-19.2%) |
| Jun 2017 | - | -$5.58 M(-30.9%) | -$30.16 M(-11.9%) |
| Mar 2017 | - | -$8.07 M(+18.9%) | -$34.23 M(-6.1%) |
| Dec 2016 | -$36.46 M(+46.5%) | -$6.79 M(-30.2%) | -$36.46 M(-1.3%) |
| Sep 2016 | - | -$9.72 M(+0.8%) | -$36.93 M(+10.2%) |
| Jun 2016 | - | -$9.65 M(-6.4%) | -$33.52 M(+10.2%) |
| Mar 2016 | - | -$10.30 M(+42.0%) | -$30.41 M(+22.2%) |
| Dec 2015 | -$24.89 M(+69.2%) | -$7.26 M(+15.0%) | -$24.89 M(+6.7%) |
| Sep 2015 | - | -$6.31 M(-3.5%) | -$23.32 M(+6.3%) |
| Jun 2015 | - | -$6.54 M(+36.8%) | -$21.94 M(+34.1%) |
| Mar 2015 | - | -$4.78 M(-16.0%) | -$16.36 M(+11.2%) |
| Dec 2014 | -$14.71 M(+26.1%) | -$5.69 M(+15.5%) | -$14.71 M(+47.2%) |
| Sep 2014 | - | -$4.93 M(+410.8%) | -$9.99 M(+6.1%) |
| Jun 2014 | - | -$964.60 K(-69.2%) | -$9.42 M(-31.2%) |
| Mar 2014 | - | -$3.13 M(+221.1%) | -$13.70 M(+17.4%) |
| Dec 2013 | -$11.66 M(+1.2%) | -$973.90 K(-77.6%) | -$11.66 M(-38.0%) |
| Sep 2013 | - | -$4.35 M(-17.0%) | -$18.83 M(+21.5%) |
| Jun 2013 | - | -$5.24 M(+379.8%) | -$15.50 M(+13.3%) |
| Mar 2013 | - | -$1.09 M(-86.6%) | -$13.67 M(-0.5%) |
| Dec 2012 | -$11.52 M(+430.5%) | -$8.14 M(+692.5%) | -$13.74 M(+141.8%) |
| Sep 2012 | - | -$1.03 M(-70.0%) | -$5.68 M(+5.5%) |
| Jun 2012 | - | -$3.42 M(+195.6%) | -$5.39 M(+106.2%) |
| Mar 2012 | - | -$1.16 M(+1338.4%) | -$2.61 M(+20.2%) |
| Dec 2011 | -$2.17 M(-59.6%) | -$80.40 K(-89.0%) | -$2.17 M(+3.8%) |
| Sep 2011 | - | -$729.60 K(+13.1%) | -$2.09 M(+53.6%) |
| Jun 2011 | - | -$644.90 K(-10.1%) | -$1.36 M(+89.9%) |
| Mar 2011 | - | -$717.40 K | -$717.40 K |
| Dec 2010 | -$5.37 M | - | - |
FAQ
- What is Cardiff Oncology annual EBITDA?
- What is the all time high annual EBITDA for Cardiff Oncology?
- What is Cardiff Oncology annual EBITDA year-on-year change?
- What is Cardiff Oncology quarterly EBITDA?
- What is the all time high quarterly EBITDA for Cardiff Oncology?
- What is Cardiff Oncology quarterly EBITDA year-on-year change?
- What is Cardiff Oncology TTM EBITDA?
- What is the all time high TTM EBITDA for Cardiff Oncology?
- What is Cardiff Oncology TTM EBITDA year-on-year change?
What is Cardiff Oncology annual EBITDA?
The current annual EBITDA of CRDF is -$45.01 M
What is the all time high annual EBITDA for Cardiff Oncology?
Cardiff Oncology all-time high annual EBITDA is -$2.17 M
What is Cardiff Oncology annual EBITDA year-on-year change?
Over the past year, CRDF annual EBITDA has changed by -$5.35 M (-13.48%)
What is Cardiff Oncology quarterly EBITDA?
The current quarterly EBITDA of CRDF is -$12.50 M
What is the all time high quarterly EBITDA for Cardiff Oncology?
Cardiff Oncology all-time high quarterly EBITDA is $2.32 M
What is Cardiff Oncology quarterly EBITDA year-on-year change?
Over the past year, CRDF quarterly EBITDA has changed by -$1.79 M (-16.68%)
What is Cardiff Oncology TTM EBITDA?
The current TTM EBITDA of CRDF is -$46.00 M
What is the all time high TTM EBITDA for Cardiff Oncology?
Cardiff Oncology all-time high TTM EBITDA is -$717.40 K
What is Cardiff Oncology TTM EBITDA year-on-year change?
Over the past year, CRDF TTM EBITDA has changed by -$1.91 M (-4.33%)